Literature DB >> 21054768

Acquirement and disappearance of HBsAg and anti-HCV in an aged population: a follow-up study in an endemic township.

Pei-Shan Tsai1, Chang-Jung Chang, Kow-Tong Chen, Kuo-Chin Chang, Shu-Fen Hung, Jing-Houng Wang, Chao-Hung Hung, Chien-Hung Chen, Po-Lin Tseng, Kwong-Ming Kee, Yi-Hao Yen, Chin-Chen Tsai, Sheng-Nan Lu.   

Abstract

BACKGROUND: HBsAg and anti-hepatitis C virus (anti-HCV) are stable markers and widely used. The seroconversion and seroclearance of HBsAg and anti-HCV are important for disease control and prognosis of diseases. AIMS: To investigate acquirement and disappearance of HBsAg and anti-HCV in an endemic area.
METHODS: Seven years after a community screening, 1002 of 2909 residents of Tzukuan Township were recruited. HBsAg, anti-HCV and alanine transaminase (ALT) were checked in all who participated and hepatitis B virus (HBV) DNA, anti-HBs, anti-HBc, HCV RNA, anti-HDV and upper abdominal ultrasonography were studied in different groups.
RESULTS: There were 461 male and 541 female residents with a mean age of 66.7 ± 8.6 years. No new HBsAg carrier was noted and the HBsAg clearance rate was 1.58% per year. One of the 17 cases with HBsAg clearance had positive HBV DNA, three had ALT elevation, two had cirrhosis and seven had anti-HBs seroconversion. Quantitative of HBsAg and HBV DNA were concordant and 78.1% subjects had low levels of titration. Anti-HBc alone contributed to 32.1% and was prominent in old age and the anti-HCV-positive group. The anti-HCV seroconversion rate was only 0.74% per year and household transmission was the only risk factor. Only 37.5% of cases with anti-HCV seroconversion had HCV viraemia and the anti-HCV seroreversion rate was 0.63% per year. The anti-HDV seroconversion rate was 0.72% per year and no subject showed anti-HDV clearance.
CONCLUSIONS: Much higher rates of HBsAg seroclearance, anti-HCV seroreversion and anti-HBc alone were noted in this endemic area and no subject showed anti-HDV clearance.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21054768     DOI: 10.1111/j.1478-3231.2010.02363.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

1.  Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.

Authors:  Kali Zhou; Caitlin Contag; Evans Whitaker; Norah Terrault
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-01-22

2.  Is hepatitis C virus core antigen an adequate marker for community screening?

Authors:  Yuan-Hung Kuo; Kuo-Chin Chang; Jing-Houng Wang; Pei-Shan Tsai; Shu-Feng Hung; Chao-Hung Hung; Chien-Hung Chen; Sheng-Nan Lu
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

3.  Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.

Authors:  Ming-Lung Yu; Ming-Lun Yeh; Pei-Chien Tsai; Ching-I Huang; Jee-Fu Huang; Chung-Feng Huang; Meng-Hsuan Hsieh; Po-Cheng Liang; Yi-Hung Lin; Ming-Yen Hsieh; Wen-Yi Lin; Nai-Jen Hou; Zu-Yau Lin; Shinn-Cherng Chen; Chia-Yen Dai; Wan-Long Chuang; Wen-Yu Chang
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

4.  Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening.

Authors:  Yuan-Hung Kuo; Kwong-Ming Kee; Nien-Tzu Hsu; Jing-Houng Wang; Chang-Chun Hsiao; Yi Chen; Sheng-Nan Lu
Journal:  PLoS One       Date:  2019-10-22       Impact factor: 3.240

5.  Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan.

Authors:  Pei-Chien Tsai; Ching-I Huang; Ming-Lun Yeh; Chung-Feng Huang; Meng-Hsuan Hsieh; Jeng-Fu Yang; Po-Yao Hsu; Po-Cheng Liang; Yi-Hung Lin; Tyng Yuan Jang; Ming-Yen Hsieh; Chia-Yen Dai; Zu-Yau Lin; Shinn-Chern Chen; Jee-Fu Huang; Ming-Lung Yu; Wan-Long Chuang; Wen-Yu Chang
Journal:  BMJ Open       Date:  2021-03-15       Impact factor: 2.692

6.  Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study).

Authors:  Jee-Fu Huang; Ming-Yen Hsieh; Yu-Ju Wei; Jen-Yu Hung; Hsuan-Ti Huang; Ching-I Huang; Ming-Lun Yeh; Chung-Feng Huang; Tyng-Yuan Jang; Po-Yao Hsu; Po-Cheng Liang; Chia-Yen Dai; Zu-Yau Lin; Ming-Lung Yu; Wan-Long Chuang
Journal:  Hepatol Int       Date:  2021-11-30       Impact factor: 9.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.